At a glance
ClinicalIndex Comparison Record- ✓Pathologically confirmed thymic carcinoma (primary or metastatic lesions)
- ✓CD5 or c-KIT positive preferred by immunohistochemistry
- ✓Unresectable advanced thymic carcinoma stage IVa/IVb (Masaoka-Koga), metastatic or recurrent, with no prior systemic chemotherapy
- ✓OR stage III (Masaoka-Koga) deemed incapable of radical resection or not eligible for curative chemoradiotherapy
- ✕Diagnosis of thymoma
- ✕Immune-related complications (myasthenia gravis, pure red cell aplasia, hypogammaglobulinemia)
- ✕Symptomatic brain metastases, carcinomatous meningitis, or spinal metastases requiring radiotherapy or surgery
- ✕Prior VEGFR-targeting antiangiogenetic agent for thymic carcinoma
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT05832827Phase 2RecruitingUpdate OverdueUpdated 32mo ago · Completion was 6mo agoFirst-line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas
In Brief
A Phase 2 clinical trial evaluating MK-3475, Lenvatinib, and 2 other interventions for Untreated Advanced or Recurrent Thymic Carcinomas. Currently recruiting, targeting 35 participants across 1 site.
Signals
Detailed Summary
A phase II, investigator-initiated, non-randomized, open-label, single-arm, multicenter study to evaluate the efficacy and safety of Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab combination for previously untreated advanced or recurrent thymic carcinomas
Study Details
Timeline
Interventions
Pembrolizumab will be administered at a dose of 200 mg by intravenous infusion every 21 days (3 weeks) for up to 35 cycles.
Lenvatinib will be administered at a dose of 8 mg orally QD every 21 days (3 weeks) for up to 4 cycles in the induction phase, followed by 20 mg QD for up to 31 cycles in the maintenance phase. Then, further maintenance therapy with lenvatinib will be allowed until progression or unacceptable adverse events.
Carboplatin will be administered at a dose of AUC 5 intravenously every 21 days (3 weeks) for up to 4 cycles in the induction phase.
Paclitaxel will be administered at a dose of 175 mg/m\^2 intravenously every 21 days (3 weeks) for up to 4 cycles in the induction phase.